Literature DB >> 30077992

In silico validation of the Autoinflammatory Disease Damage Index.

Nienke M Ter Haar1,2, Amber Laetitia Justine van Delft3, Kim Valerie Annink3, Henk van Stel3, Sulaiman M Al-Mayouf4, Gayane Amaryan5, Jordi Anton6, Karyl S Barron7, Susanne Benseler8, Paul A Brogan9, Luca Cantarini10, Marco Cattalini11, Alexis-Virgil Cochino12, Fabrizio de Benedetti13, Fatma Dedeoglu14, Adriana Almeida de Jesus15, Erkan Demirkaya16, Pavla Dolezalova17, Karen L Durrant18, Giovanna Fabio19, Romina Gallizzi20, Raphaela Goldbach-Mansky15, Eric Hachulla21, Veronique Hentgen22, Troels Herlin23, Michaël Hofer24,25, Hal M Hoffman26, Antonella Insalaco27, Annette F Jansson28,29, Tilmann Kallinich28, Isabelle Kone-Paut30, Anna Kozlova31, Jasmin Beate Kuemmerle-Deschner32, Helen J Lachmann33, Ronald M Laxer34, Alberto Martini35, Susan Nielsen36, Irina Nikishina37, Amanda K Ombrello38, Seza Özen39, Efimia Papadopoulou-Alataki40, Pierre Quartier41, Donato Rigante42, Ricardo Russo43, Anna Simon44, Maria Trachana45, Yosef Uziel46, Angelo Ravelli47, Grant Schulert48,49, Marco Gattorno47, Joost Frenkel3.   

Abstract

INTRODUCTION: Autoinflammatory diseases can cause irreversible tissue damage due to systemic inflammation. Recently, the Autoinflammatory Disease Damage Index (ADDI) was developed. The ADDI is the first instrument to quantify damage in familial Mediterranean fever, cryopyrin-associated periodic syndromes, mevalonate kinase deficiency and tumour necrosis factor receptor-associated periodic syndrome. The aim of this study was to validate this tool for its intended use in a clinical/research setting.
METHODS: The ADDI was scored on paper clinical cases by at least three physicians per case, independently of each other. Face and content validity were assessed by requesting comments on the ADDI. Reliability was tested by calculating the intraclass correlation coefficient (ICC) using an 'observer-nested-within-subject' design. Construct validity was determined by correlating the ADDI score to the Physician Global Assessment (PGA) of damage and disease activity. Redundancy of individual items was determined with Cronbach's alpha.
RESULTS: The ADDI was validated on a total of 110 paper clinical cases by 37 experts in autoinflammatory diseases. This yielded an ICC of 0.84 (95% CI 0.78 to 0.89). The ADDI score correlated strongly with PGA-damage (r=0.92, 95% CI 0.88 to 0.95) and was not strongly influenced by disease activity (r=0.395, 95% CI 0.21 to 0.55). After comments from disease experts, some item definitions were refined. The interitem correlation in all different categories was lower than 0.7, indicating that there was no redundancy between individual damage items.
CONCLUSION: The ADDI is a reliable and valid instrument to quantify damage in individual patients and can be used to compare disease outcomes in clinical studies. © Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  familial Mediterranean fever; fever syndromes; inflammation

Mesh:

Year:  2018        PMID: 30077992     DOI: 10.1136/annrheumdis-2018-213725

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  8 in total

1.  Pattern and diagnostic evaluation of systemic autoinflammatory diseases other than familial Mediterranean fever among Arab children: a multicenter study from the Pediatric Rheumatology Arab Group (PRAG).

Authors:  Sulaiman M Al-Mayouf; Abdulaziz Almutairi; Safiya Albrawi; Basil M Fathalla; Raed Alzyoud; Abdullatif AlEnazi; Mohammed Abu-Shukair; Adel Alwahadneh; Abdullah Alsonbul; Mabruka Zlenti; Ebtisam Khawaja; Awatif Abushhaiwia; Khulood Khawaja; Zakiya AlMosawi; Wafa Madan; Muna Almuatiri; Nora Almuatiri
Journal:  Rheumatol Int       Date:  2019-11-18       Impact factor: 2.631

2.  Children and Adults with PFAPA Syndrome: Similarities and Divergences in a Real-Life Clinical Setting.

Authors:  Ludovico Luca Sicignano; Donato Rigante; Beatrice Moccaldi; Maria Grazia Massaro; Stefano Delli Noci; Isabella Patisso; Giovanna Capozio; Elena Verrecchia; Raffaele Manna
Journal:  Adv Ther       Date:  2020-12-14       Impact factor: 3.845

3.  Follow the complex bread crumbs: A review of autoinflammation for the general paediatrician.

Authors:  Paul Tsoukas; Ronald M Laxer
Journal:  Paediatr Child Health       Date:  2019-07-18       Impact factor: 2.253

4.  Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network.

Authors:  Antonio Vitale; Laura Obici; Marco Cattalini; Giuseppe Lopalco; Giampaolo Merlini; Nicola Ricco; Alessandra Soriano; Francesco La Torre; Elena Verrecchia; Antonella Insalaco; Lorenzo Dagna; Masen Abdel Jaber; Davide Montin; Giacomo Emmi; Luisa Ciarcia; Sara Barneschi; Paola Parronchi; Piero Ruscitti; Maria Cristina Maggio; Ombretta Viapiana; Jurgen Sota; Carla Gaggiano; Roberto Giacomelli; Ludovico Luca Sicignano; Raffaele Manna; Alessandra Renieri; Caterina Lo Rizzo; Bruno Frediani; Donato Rigante; Luca Cantarini
Journal:  Front Med (Lausanne)       Date:  2021-07-08

Review 5.  Familial Mediterranean Fever: Assessing the Overall Clinical Impact and Formulating Treatment Plans.

Authors:  Raffaele Manna; Donato Rigante
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-05-01       Impact factor: 3.122

Review 6.  Management of Monogenic IL-1 Mediated Autoinflammatory Diseases in Childhood.

Authors:  Tatjana Welzel; Susanne M Benseler; Jasmin B Kuemmerle-Deschner
Journal:  Front Immunol       Date:  2021-03-18       Impact factor: 7.561

Review 7.  Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?

Authors:  Tatjana Welzel; Jasmin B Kuemmerle-Deschner
Journal:  J Clin Med       Date:  2021-01-01       Impact factor: 4.241

8.  Improvement of Liver Involvement in Familial Mediterranean Fever After the Introduction of Canakinumab: A Case Report.

Authors:  Maria Grazia Massaro; Maurizio Pompili; Luca L Sicignano; Fabrizio Pizzolante; Elena Verrecchia; Fabio M Vecchio; Donato Rigante; Raffaele Manna
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-09-01       Impact factor: 2.576

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.